Graphic designer Thesis Last March, I made my debut in Seeking Alpha by analyzing Takeda Pharmaceutical Company Limited (NYSE:TAK). In the article, I highlighted that the company was showing signs of improvement, despite the decline of revenue from key areas such as oncology and neurosciences. Among those signs were the revenue increase observed from the gastrointestinal and inflammation sector, the approval of Eohilia, the announcement of Milano Furuta as new Chief Financial Officer (CFO), who took the rol ...